Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL416P is a **pseudogene** derived from the 7SL RNA gene family, specifically annotated as "RNA, 7SL, cytoplasmic 416, pseudogene"[1][5][6][7]. The 7SL RNA itself is a structural component of the signal recognition particle (SRP), which is essential for protein targeting to the endoplasmic reticulum in eukaryotic cells[3][4]. However, RN7SL416P, as a pseudogene, is a non-functional remnant of a formerly active gene. It does not encode a functional RNA molecule or protein and is not considered an active participant in cellular processes[1][5][6][7]. Pseudogenes such as RN7SL416P are widespread in the human genome and result from the integration of copied or mutated 7SL RNA sequences that have lost the ability to generate a functional RNA transcript[5][6]. RN7SL416P is not recognized or used as a therapeutic target and has no known biological or pharmacological relevance[1][5][6][7]. RN7SL416P is an example of a **pseudogene** and should not be considered a molecular target for drug development, therapeutic intervention, or biomarker research.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 416, pseudogene (RN7SL416P).